Haag et al. evaluated the useof cholesterol-lowering drugs and divided them into three classes: lipophilicstatins (simvastatin, atorvastatin, cerivastatin), hydrophilic statins(pravastatin, fluvastatin, rosuvastatin), and non-statin cholesterol loweringdrugs (fibrates, bile acid binding resins or nicotinic acid and derivatives).Use of statins, despite their lipophilicity, but not use of non-statincholesterol lowering drugs, was associated with a reduced risk of AD comparedwith never users.31 Thisprotection was effective independent of APOE4 genotype status. This evidence concerns the gene APOE and Alzheimer disease.